𝔖 Bobbio Scriptorium
✦   LIBER   ✦

MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administration

✍ Scribed by James R. Ewing; Stephen L. Brown; Tavarekere N. Nagaraja; Hassan Bagher-Ebadian; Ramesh Paudyal; Swayamprava Panda; Robert A. Knight; Guangliang Ding; Quan Jiang; Mei Lu; Joseph D. Fenstermacher


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
503 KB
Volume
27
Category
Article
ISSN
1053-1807

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Purpose

To demonstrate in the rat 9L cerebral tumor model that repeated MRI measurements can quantitate acute changes in the blood‐brain distribution of Gadomer after dexamethasone administration.

Materials and Methods

A total of 16 Fischer 344 rats were studied at 7T, 15 days after cerebral implantation of a 9L tumor. MRI procedures employed a T‐One by Multiple Read Out Pulses (TOMROP) sequence to estimate R~1~ (R~1~ = 1/T~1~) at 145‐second intervals before and after administration of Gadomer (Bayer), a macromolecular contrast agent (CA). Two baseline studies preceded Gadomer administration and 10 subsequent R~1~ maps tracked CA concentration in blood and brain for 25 minutes. Thereafter, either dexamethasone (N = 10) or normal saline (N = 6) was administered intravenously. A total of 90 minutes later a second series of 12 TOMROP measurements of Gadomer distribution was performed. The influx constant, K~1~, plasma distribution volume, v~D~, backflux constant, k~b~, and interstitial space, v~e~, were determined, and the test‐retest differences of each of four vascular parameters were calculated.

Results

Dexamethasone decreased K~1~ approximately 60% (P = 0.02), lowered k~b~ and v~D~ (P = 0.03 and P < 0.01, respectively), and marginally but insignificantly decreased v~e~.

Conclusion

This noninvasive MRI technique can detect drug effects on blood‐brain transfer constants of CAs within two hours of administration. J. Magn. Reson. Imaging 2008;27:1430–1438. © 2008 Wiley‐Liss, Inc.